ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Globe Newswire•19/10/2026•08:00 ET
0
Key Highlights
- ➤ORIC to review enozertinib Phase 1b data in first-line NSCLC on October 23
- ➤Enozertinib targets EGFR atypical mutations in treatment-naive metastatic NSCLC
- ➤Rinzimetostat-darolutamide Phase 3 mCRPC study featured at ESMO 2026
- ➤Three ORIC poster presentations scheduled during ESMO Congress 2026
Expert Statements
Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine
“the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations”
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET
Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations
Get started
Create a free account to read the full story.